Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / LCP2



This biomarker is also known as:
  • SH2 domain-containing leukocyte protein of 76kD,
  • lymphocyte cytosolic protein 2 (SH2 domain-containing leukocyte protein of 76kD),
  • 76 kDa tyrosine phosphoprotein,
  • lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa),
  • lymphocyte cytosolic protein 2,
  • SLP-76,
  • SH2 domain-containing leukocyte protein of 76 kDa,
  • SLP76,
  • SLP-76 tyrosine phosphoprotein,

View in BioMuta


LCP2, previously known as SLP76, functions as an adaptor or scaffolding protein. LCP2 has three modular domains. The amino-terminal end has an acidic region that includes a PEST domain and several tyrosine residues which are phosphorylated following TCR ligation. LCP2 also contains a central proline-rich domain and a COOH-terminal SH2 domain.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data is available.

Performance Comment

LCP2 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.